Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 8/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6824364 | 0.97 | GRM5 (0.51) | GRM5KMT2AMEN1HPGDCNR1 | |
| SCHEMBL423467 | 0.84 | KMT2A (0.59) | GRM5KMT2AMEN1HPGDCNR1 | |
| SCHEMBL1427046 | 0.81 | MEN1 (0.59) | GRM5KMT2AMEN1HPGDCNR1 | |
| SCHEMBL23675259 | 0.77 | HPGD (0.52) | GRM5HPGDCNR1TSHRALDH1A1 | |
| SCHEMBL29994736 | 0.77 | HPGD (0.52) | GRM5HPGDCNR1TSHRALDH1A1 | |
| SCHEMBL6821163 | 0.77 | HPGD (0.49) | GRM5KMT2AHPGDCNR1TSHR | |
| SCHEMBL990157 | 0.77 | GRM5 (0.64) | GRM5KMT2AMEN1HPGDALDH1A1 | |
| SCHEMBL15500046 | 0.74 | KCNQ3 (0.40) | KMT2AMEN1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL427869 | 0.74 | HCAR2 (0.47) | KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13859498 | 0.74 | KMT2A (0.40) | KMT2AMEN1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239253-B1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-8415359-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-26 | — | — | US | disclosed |
| US-8017610-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2239253-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | GRM5 245/4885KMT2A 2958/4885MEN1 3897/4885 |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | GRM5 245/4885KMT2A 2958/4885MEN1 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.